Sarah C Tinker1, Jennita Reefhuis1, Rebecca H Bitsko1, Suzanne M Gilboa1, Allen A Mitchell2, Emmy L Tran1,3, Martha M Werler4, Cheryl S Broussard1. 1. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Slone Epidemiology Center at Boston University, Boston, Massachusetts. 3. Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, Tennessee. 4. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND: Benzodiazepine medications can be used to treat anxiety, a condition affecting 15% of women of childbearing age in the United States. Studies have shown conflicting results for the association between benzodiazepine use during pregnancy and birth defects. METHODS: We analyzed 1997-2011 data from the National Birth Defects Prevention Study, a multisite, population-based case-control study. We assessed the prevalence of and factors associated with benzodiazepine use in pregnancy among mothers of live-born infants without a birth defect (control mothers). We used logistic regression to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the association between specific birth defects and benzodiazepine use; we estimated crude odds ratios (cORs) for defect categories with 3-4 exposed cases. RESULTS: Exposure to benzodiazepines during pregnancy was rare (N = 93/11,614; 0.8%). Benzodiazepine use was more common among control mothers who were ≥30 years, non-Hispanic white, had more education, smoked, and took antidepressant medication. We observed significantly elevated ORs for any benzodiazepine and Dandy-Walker malformation (cOR: 3.1; 95% CI: 1.1, 8.6); for alprazolam and anophthalmia or microphthalmia (cOR: 4.0; 95% CI: 1.2, 13.1) and esophageal atresia or stenosis (aOR: 2.7; 95% CI: 1.2, 5.9); and lorazepam and pulmonary valve stenosis (cOR: 4.1; 95% CI: 1.2, 14.2), but sample sizes were limited and therefore CIs were wide. CONCLUSIONS: Our findings suggest that benzodiazepines use is rare and may be associated with risk for certain birth defects. However, these results need replication and should be interpreted with caution. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Benzodiazepine medications can be used to treat anxiety, a condition affecting 15% of women of childbearing age in the United States. Studies have shown conflicting results for the association between benzodiazepine use during pregnancy and birth defects. METHODS: We analyzed 1997-2011 data from the National Birth Defects Prevention Study, a multisite, population-based case-control study. We assessed the prevalence of and factors associated with benzodiazepine use in pregnancy among mothers of live-born infants without a birth defect (control mothers). We used logistic regression to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the association between specific birth defects and benzodiazepine use; we estimated crude odds ratios (cORs) for defect categories with 3-4 exposed cases. RESULTS: Exposure to benzodiazepines during pregnancy was rare (N = 93/11,614; 0.8%). Benzodiazepine use was more common among control mothers who were ≥30 years, non-Hispanic white, had more education, smoked, and took antidepressant medication. We observed significantly elevated ORs for any benzodiazepine and Dandy-Walker malformation (cOR: 3.1; 95% CI: 1.1, 8.6); for alprazolam and anophthalmia or microphthalmia (cOR: 4.0; 95% CI: 1.2, 13.1) and esophageal atresia or stenosis (aOR: 2.7; 95% CI: 1.2, 5.9); and lorazepam and pulmonary valve stenosis (cOR: 4.1; 95% CI: 1.2, 14.2), but sample sizes were limited and therefore CIs were wide. CONCLUSIONS: Our findings suggest that benzodiazepines use is rare and may be associated with risk for certain birth defects. However, these results need replication and should be interpreted with caution. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Suzanne M Gilboa; Cheryl S Broussard; Owen J Devine; Kara N Duwe; Audrey L Flak; Sheree L Boulet; Cynthia A Moore; Martha M Werler; Margaret A Honein Journal: Am J Med Genet C Semin Med Genet Date: 2011-07-15 Impact factor: 3.908
Authors: Sonja A Rasmussen; Richard S Olney; Lewis B Holmes; Angela E Lin; Kim M Keppler-Noreuil; Cynthia A Moore Journal: Birth Defects Res A Clin Mol Teratol Date: 2003-03
Authors: Tim F Oberlander; William Warburton; Shaila Misri; Wayne Riggs; Jaafar Aghajanian; Clyde Hertzman Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2008-02
Authors: Carlos Aparecido da Silva Junior; Luís Gustavo A Patrone; Vivian Biancardi; Heloísa H Vilela-Costa; Danuzia A Marques; Caroline Cristina-Silva; Kaoma Stephani da Costa Silva; Kênia C Bícego; Raphael E Szawka; Luciane H Gargaglioni Journal: Pflugers Arch Date: 2022-07-25 Impact factor: 4.458
Authors: Thiago C Genaro-Mattos; Korinne B Klingelsmith; Luke B Allen; Allison Anderson; Keri A Tallman; Ned A Porter; Zeljka Korade; Károly Mirnics Journal: ACS Pharmacol Transl Sci Date: 2021-02-17
Authors: Laura Palagini; Alessandra Bramante; Chiara Baglioni; Nicole Tang; Luigi Grassi; Ellemarije Altena; Anna F Johann; Pierre Alexis Geoffroy; Giovanni Biggio; Claudio Mencacci; Verinder Sharma; Dieter Riemann Journal: Arch Womens Ment Health Date: 2022-04-13 Impact factor: 4.405